Last reviewed · How we verify
Gatifloxacin Ophthalmic
At a glance
| Generic name | Gatifloxacin Ophthalmic |
|---|---|
| Sponsor | Carolina Eyecare Physicians, LLC |
| Drug class | Quinolone Antimicrobial [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Worsening of conjunctivitis
- Eye irritation
- Dysgeusia
- Eye pain
- Chemosis
- Conjunctival hemorrhage
- Dry eye
- Eye discharge
- Eyelid edema
- Headache
- Increased lacrimation
- Keratitis
Serious adverse events
- Anaphylactic reactions
- Angioedema (pharyngeal, oral or facial edema)
- Dyspnea
- Eye swelling (corneal and conjunctival edema)
- Hypersensitivity
- Corneal endothelial cell injury
- Blepharitis
- Vision blurred
- Allergic dermatitis
- Urticaria
Key clinical trials
- Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PHASE3)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis (PHASE3)
- Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery (NA)
- Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gatifloxacin Ophthalmic CI brief — competitive landscape report
- Gatifloxacin Ophthalmic updates RSS · CI watch RSS
- Carolina Eyecare Physicians, LLC portfolio CI